USPTO Examiner PURDY KYLE A - Art Unit 1611

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18897019Pathogenic Affinity Pathway of Infectious or Parasitic Organisms for Nanogram and Picogram Dosimetry Prophylaxis or CureSeptember 2024December 2024Allow300YesNo
18894811THERAPEUTIC METHODS USING BUPROPION HYDROBROMIDE TO TREAT MAJOR DEPRESSIVE DISORDERSeptember 2024March 2025Allow610NoNo
18739339PUERARIA LOBATA NANO-SILVER COMPOSITE HYDROSOL, PREPARATION METHOD AND APPLICATION THEREOFJune 2024November 2024Allow510NoNo
18677521PHARMACEUTICAL COMPOSITION AND METHOD FOR SUPPRESSING DEGENERATIONMay 2024September 2025Allow1610NoNo
18650564ANTIBIOTIC-FREE ANTIMICROBIAL FEED ADDITIVES AND ANTIMICROBIAL COMPOSITIONSApril 2024December 2025Abandon2020NoNo
18650973METHODS FOR INCREASING SEED YIELD AND OIL SEED PRODUCTIONApril 2024August 2025Abandon1521YesNo
18647695ENHANCED FORMULATIONS, COMPOSITIONS AND METHODS FOR PEST CONTROLApril 2024October 2025Allow1730NoNo
18413304Diphenyl Tablets and Methods of Preparing the SameJanuary 2024March 2025Abandon1410NoNo
18405062COMPOSITION AND METHOD FOR IMPROVING AGRONOMIC TRAITS OF A PLANTJanuary 2024March 2025Allow1521YesNo
18541832INTRAOPERATIVE TOPICALLY-APPLIED NON-IMPLANTABLE RAPID RELEASE PATCHDecember 2023February 2025Allow1420YesNo
18524738LIQUISOFT CAPSULESNovember 2023January 2025Allow1410YesNo
18495938Materials and Methods Relating to Stabilised Polymeric Silicate CompositionsOctober 2023July 2025Abandon2111NoNo
18384042PREPARATION METHOD FOR MODIFIED NANO-ZINC OXIDE POWDEROctober 2023April 2024Allow510NoNo
18286549SYSTEMS AND METHODS FOR TREATING VITILIGO USING ETHYL PYRUVATE AND OTHER COMPOUNDSOctober 2023March 2026Abandon2910NoNo
18483463COMPOSITIONS, SYSTEMS, AND METHODS FOR INCREASED PLANT QUALITYOctober 2023May 2025Allow1921YesNo
18242083ENHANCED CURCUMA LONGA PRODUCTIVITY AND MEDICINAL VALUES BY USING MORINGA OLEIFERA LEAF EXTRACTSeptember 2023January 2024Allow410NoNo
18459781BIOMASS-DERIVED CARBON PARTICLE, AND PREPARATION METHOD AND USE THEREOFSeptember 2023November 2025Abandon2721NoNo
18232120PHOTOSTABLE COMPOSITIONS COMPRISING PARA-ALKOXYL PHENYL SUBSTITUTED PROPENOIC ACID (APP) COPOLYMER DERIVATIVESAugust 2023July 2024Allow1210NoNo
18356932N-Oxide and Ectoine Monomers, Polymers, Their Compositions, and Related MethodsJuly 2023December 2024Abandon1710NoNo
18339440USE OF MATERIALS INCORPORATING MICROPARTICLES FOR AVOIDING THE PROLIFERATION OF CONTAMINANTSJune 2023January 2026Allow3121YesNo
18268232SUTHERLANDIA EXTRACT AND THE USE THEREOF IN THE MANUFACTURE OF A MEDICAMENTJune 2023March 2026Abandon3301NoNo
18211252NANOCOMPOSITE INCLUDING WATER-SOLUBLE NANO-POLYMER AND MESOPOROUS SILICA NANOPARTICLES ENCAPSULATED WITH AZOLE DERIVATIVESJune 2023August 2023Allow200NoNo
18334055COMPOSITIONS FOR CONTROLLING ARTHROPODSJune 2023September 2024Abandon1521NoNo
18334017COMPOSITIONS FOR CONTROLLING ARTHROPODSJune 2023September 2024Abandon1521NoNo
18327798COMPOSITION FOR EXTERMINATING FISH PARASITESJune 2023March 2026Abandon3310NoNo
18317646STABLE AVIPTADIL FORMULATIONSMay 2023December 2023Abandon710NoNo
18249202COMPOSITION FOR PREVENTING OR TREATING LUNG CANCER, COMPRISING A COMPOUND ISOLATED FROM CEPHALOTAXUS EXTRACT AS AN ACTIVE INGREDIENTApril 2023February 2026Allow3420NoNo
18194011ANTIVIRAL ARTICLESMarch 2023August 2024Abandon1610NoNo
18189298LIQUID CONCENTRATE FOR PRESERVATIONMarch 2023January 2025Allow2230YesYes
18180801SINGLE VIAL VACCINE FORMULATIONSMarch 2023August 2025Allow2940YesNo
18174090STOVE WITH MOSQUITO REPELLENT COMPONENTFebruary 2023September 2023Allow710NoNo
18107243Solid Pharmaceutical Compositions for Treating HCVFebruary 2023September 2024Abandon1910NoNo
18157964MODULAR APPARATUS FOR COLLECTING CANNABIS TRICHOMESJanuary 2023January 2026Abandon3601NoNo
18100225Antibacterial Composition and its Use in Treating Bacterial InfectionsJanuary 2023May 2024Allow1620YesNo
18017027NITINOL NANOFIBERSJanuary 2023November 2023Allow911YesNo
18006052A METHOD OF CONTROLLING PESTJanuary 2023January 2026Abandon3610NoNo
18005734ISOLATION OF CANNABINOIDS USING MESOPOROUS MATERIALSJanuary 2023December 2025Abandon3501NoNo
18153696STRESS MANAGEMENT IN LIVESTOCKJanuary 2023February 2025Abandon2530NoNo
18147229REFINING METHODDecember 2022November 2025Allow3510YesNo
18079931COMPOSITION FOR OBTAINING A NATURAL BIOACTIVE FOR ONCOLOGIC THERAPIESDecember 2022April 2025Allow2800YesNo
18074482METHOD AND SYSTEM FOR ADVANCED TECHNOLOGY PACKAGING AND DELIVERY OF ACTIVE CHEMICAL INGREDIENTSDecember 2022September 2025Abandon3321NoNo
17988575ENPP1 MODULATORS AND USES THEREOFNovember 2022December 2025Abandon3701NoNo
17980684BIOMIMETIC NANOFIBER TISSUE SCAFFOLDSNovember 2022January 2024Abandon1410NoNo
17969266PHARMACEUTICAL COMPOSITION FOR IMPROVING HEALTH, CURE ABNORMALITIES AND DEGENERATIVE DISEASE, ACHIEVE ANTI-AGING EFFECT OF THERAPY AND THERAPEUTIC EFFECT ON MAMMALS AND METHOD THEREOFOctober 2022February 2024Allow1530NoNo
17995905FACE MASK, COMPOSITES, IRON-IRON OXIDE COMPOSITIONS AND METHODS OF MANUFACTURE AND USE THEREOFOctober 2022March 2025Allow2900YesNo
17916864COMPOSITION FOR CONTROL OF PESTS AND METHOD OF USE THEREOFOctober 2022October 2025Abandon3710NoNo
17916614A MODIFIED BENTONITE, A COMPOSITION BASED ON A MODIFIED BENTONITE AND A METHOD FOR MANUFACTURING THEREOFOctober 2022February 2026Abandon4011NoNo
17935773ANTIMICROBIAL MEDICAL BIOMATERIAL AND A METHOD OF PREPARING THE SAMESeptember 2022August 2023Allow1110NoNo
17944839LUBRICATING MEMBER COMPRISING POLYGLUTAMIC ACIDSeptember 2022September 2023Abandon1210YesNo
17943772GLASSES AND GLASS-CERAMICS AND METHODS OF MAKING THEMSeptember 2022November 2025Allow3821NoNo
17911146ANTIMICROBIAL MEMBERSeptember 2022August 2025Abandon3501NoNo
17896662DELIVERY SYSTEMS FOR RELEASE OF ACTIVE COMPOUNDSAugust 2022September 2025Abandon3610NoNo
17888471POWDER DISINFECTANT COMPOSITIONSAugust 2022November 2025Allow3921YesNo
17817919Oxime Cross-Linked Biocompatible Polymer Hydrogels and Methods of Use ThereofAugust 2022July 2024Abandon2320NoNo
17797249CONTROLLED-RELEASE FORMULATION FOR HEARING LOSS AND PREPARATION METHOD THEREFORAugust 2022May 2025Allow3401YesNo
17879259Microparticle Enabled Delivery Structures, Methods of Preparing and Using SameAugust 2022June 2025Abandon3530NoNo
17857543Nano-zinc oxide-supported bacterial cellulose microfiber-alginate fiber compositeJuly 2022July 2025Allow3701YesNo
17842376HYPERBRANCHED POLYGLYCEROL-COATED PARTICLES AND METHODS OF MAKING AND USING THEREOFJune 2022October 2023Allow1610NoNo
17837103MICRONUTRIENT FORMULATIONS THAT CONTROL PLANT PATHOGENSJune 2022March 2024Abandon2111NoNo
17779885METHOD FOR IMPROVING HOLDING POWER OF ADHESIVE AGENT LAYER OF ROPINIROLE-CONTAINING PATCH, AND ROPINIROLE-CONTAINING PATCH WITH IMPROVED HOLDING POWERMay 2022September 2025Abandon4010NoNo
17756210METHOD FOR EXTRACTING ACTIVE COMPONENTS FROM PLANTS AND DEVICES FOR SUCH PURPOSEMay 2022August 2025Abandon3901NoNo
17663296SURFACES AND COATING COMPOSITIONS HAVING ANTIFOULING, ANTITHROMBOTIC, AND ANTIBACTERIAL PROPERTIES AND METHODS OF MAKINGMay 2022January 2025Allow3211YesNo
17741358COMPOSITION AND METHOD FOR CONTROLLED DRUG RELEASE FROM A TISSUEMay 2022April 2025Abandon3540NoNo
17727213REGENERATIVE BIOACTIVE SUSPENSION DERIVED FROM FRESHLY DISAGGREGATED TISSUE AND METHODS OF USE IN CLINICAL THERAPIESApril 2022June 2023Abandon1321NoNo
17768532USE OF A FLAVANOID EXTRACT OBTAINED FROM THE SPECIES TALIPARITI ELATUM SW, FORMULATIONS COMPRISING SAME AND TREATMENT METHODApril 2022May 2025Abandon3701NoNo
17718399Hair restructuring association comprising a quaternary ammonium salt and a sulpho-derivative of vegetable fatty acidsApril 2022March 2026Allow4741YesNo
17766044INTESTINAL-ENVIRONMENT-IMPROVING AGENTApril 2022July 2025Abandon3910NoNo
17704306LIQUISOFT CAPSULESMarch 2022August 2023Allow1710NoNo
17642769BIOLOGICAL TISSUE ADHESIVE SHEET, BIOLOGICAL TISSUE REINFORCEMENT MATERIAL KIT, AND METHOD FOR PRODUCING BIOLOGICAL TISSUE ADHESIVE SHEETMarch 2022November 2024Abandon3230NoNo
17687939STAMINA-IMPROVING COMPOSITION AND STAMINA-IMPROVING NATURAL TEA COMPRISING SAMEMarch 2022March 2025Allow3610YesNo
17683803MESOPOROUS SILICA NANOPARTICLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONSMarch 2022November 2025Abandon4550NoNo
17639271PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOFFebruary 2022February 2026Allow4830YesNo
17803133Topical Skin TreatmentFebruary 2022June 2023Allow1500YesNo
17677419LIGHT-ACTIVATED CHLORINE DIOXIDE-RELEASING POWDER AND METHOD OF MANUFACTUREFebruary 2022February 2024Allow2421YesYes
17671594ANTIBACTERIAL AND ANTIFUNGAL POLYESTER MATERIALFebruary 2022March 2024Allow2520YesNo
17585504FORMULATIONS FOR CORNEAL APPLICATIONJanuary 2022February 2024Abandon2541YesYes
17605483COMPOSITION COMPRISING ACTINIDIA POLYGAMA EXTRACT FOR ALLEVIATING SKIN DAMAGE OR MOISTURIZING SKINJanuary 2022February 2025Abandon4010NoNo
17582015ANTIVIRAL COMPOSITION, ANTIVIRAL PROTECTIVE FILM AND MANUFACTURING METHOD THEREOFJanuary 2022August 2025Abandon4230YesNo
17628449METHOD FOR EXTRACTIONJanuary 2022April 2025Abandon3901NoNo
17597488ARTICLES CONTAINING A CROSSLINKED GUANIDINYL-CONTAINING POLYMER AND USES THEREOFJanuary 2022January 2025Allow3620YesYes
17624851MEDICINE FOR TREATING PULMONARY MYCOSISJanuary 2022April 2025Abandon3910NoNo
17567892TryNOVID Boosts Immune System Against Viruses and VariantsJanuary 2022August 2024Allow3100YesNo
17567599COMPOSITIONS AND ARTICLES COMPRISING COMPLEXES OF 1-METHYLCYCLOPROPENE AND ALPHA-CYCLODEXTRINJanuary 2022February 2024Allow2520YesNo
17646557ANTIVIRAL METAL TREATMENTS FOR FIBER SUBSTRATES, FILTER MEDIA HAVING ANTIVIRAL METAL TREATMENTS, AND PROCESSES FOR TREATING FIBER SUBSTRATESDecember 2021July 2025Abandon4250YesNo
17646655HYDROXIDES MONOLAYER NANOPLATELET AND METHODS OF PREPARING SAMEDecember 2021November 2024Abandon3421YesNo
17622541PHARMACEUTICAL COMPOSITION FOR PREVENTING HAIR LOSS OR PROMOTING HAIR GROWTH, COMPRISING GINSENOSIDE RG4 OR MIXTURE (RGX 365) OF GINSENOSIDES RG2, RG4, RG6, AND RH1 AS ACTIVE INGREDIENTDecember 2021June 2025Allow4111NoNo
17644745COLLOIDAL PARTICLE FORMULATIONS WITH ADVANCED FUNCTIONALITYDecember 2021August 2023Allow2021YesNo
17551719INSECT CONTROL PRODUCT FOR ANIMALSDecember 2021September 2024Abandon3320NoNo
17618013PLANT EXTRACT MIXTURE FOR USE IN THE PREVENTION AND/OR TREATMENT OF CHRONIC INFLAMMATORY BOWEL DISEASESDecember 2021January 2025Abandon3710NoNo
17548976Use Of A Composition For The Pigmentation Of Hair And HairsDecember 2021May 2025Abandon4110NoNo
17617009AN ANTIMICROBIAL COATING COMPOSITIONDecember 2021February 2025Abandon3901NoNo
17539795Anti-Psychotic Composition and Treatment MethodsDecember 2021September 2025Allow4620YesNo
17534667METHOD OF TREATING OR AMELIORATING SKIN CONDITIONS WITH A MAGNETIC DIPOLE STABILIZED SOLUTIONNovember 2021August 2023Abandon2110NoNo
17612863NANOPARTICLES COMPRISING ENZALUTAMIDENovember 2021September 2025Abandon4511NoNo
17611137GREEN FORMULATION TO REDUCE VOLATILITY AND LEACHING OF PESTICIDESNovember 2021August 2025Abandon4521NoNo
17453101METHODS AND COMPOSITIONS FOR TREATING HYPERHIDROSISNovember 2021June 2023Allow1910NoNo
17506967PHARMACEUTICAL COMPOSITION COMPRISING EXTRACT FROM CAMELLIA JAPONICA AS ACTIVE INGREDIENT FOR PREVENTION AND TREATMENT OF VIRAL INFECTIONOctober 2021December 2024Abandon3810NoNo
17417992COMPOSITION FOR PREVENTING OR TREATING SKIN DISEASES COMPRISING BRIDALWREATH SPIREAOctober 2021May 2025Abandon4620NoNo
17600910VARIOUS USES OF THE NANOPARTICULATE COMPOUND OF TITANIUM DIOXIDE FUNCTIONALIZEDOctober 2021April 2024Abandon3020NoNo
17600793SYNERGISTIC HERBAL COMPOSITIONS FOR PREVENTION, TREATMENT OR CONTROL OF PAIN AND/OR CARTILAGE REGENERATIONOctober 2021June 2025Abandon4521YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PURDY, KYLE A.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
62
Examiner Affirmed
49
(79.0%)
Examiner Reversed
13
(21.0%)
Reversal Percentile
34.2%
Lower than average

What This Means

With a 21.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
251
Allowed After Appeal Filing
40
(15.9%)
Not Allowed After Appeal Filing
211
(84.1%)
Filing Benefit Percentile
18.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 15.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner PURDY, KYLE A - Prosecution Strategy Guide

Executive Summary

Examiner PURDY, KYLE A works in Art Unit 1611 and has examined 1,014 patent applications in our dataset. With an allowance rate of 39.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.

Allowance Patterns

Examiner PURDY, KYLE A's allowance rate of 39.6% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by PURDY, KYLE A receive 3.00 office actions before reaching final disposition. This places the examiner in the 86% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PURDY, KYLE A is 42 months. This places the examiner in the 17% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +39.2% benefit to allowance rate for applications examined by PURDY, KYLE A. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 9.6% of applications are subsequently allowed. This success rate is in the 5% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 23.1% of cases where such amendments are filed. This entry rate is in the 30% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 41.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 39% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 56.6% of appeals filed. This is in the 29% percentile among all examiners. Of these withdrawals, 35.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 79.7% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 4.0% of allowed cases (in the 83% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.0% of allowed cases (in the 68% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.